Trastuzumab Cardiac Side Effects: Only Time Will Tell
Author:
Affiliation:
1. Jurevinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.04.1558
Reference8 articles.
1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
3. ErbB2 Pathways in Heart and Neural Diseases
4. Essential Roles of Her2/erbB2 in Cardiac Development and Function
5. Neuregulin Receptor ErbB2 Localization at T-tubule in Cardiac and Skeletal Muscle
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study;Anti-Cancer Drugs;2022-06-20
2. Antibody mutations favoringpH‐dependent binding in solid tumor microenvironments: Insights from large‐scale structure‐based calculations;Proteins: Structure, Function, and Bioinformatics;2022-04-13
3. Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker;Canadian Journal of Physiology and Pharmacology;2018-07
4. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer;Breast Cancer Research and Treatment;2013-03-12
5. Personalizing cardiovascular disease prevention among breast cancer survivors;Current Opinion in Cardiology;2012-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3